```
NEWS 3 FEB 28 PATDPAFULL - New display fields provide for legal status
                data from INPADOC
NEWS 4 FEB 28 BABS - Current-awareness alerts (SDIs) available
NEWS 5 MAR 02 GBFULL: New full-text patent database on STN
NEWS 6 MAR 03 REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS 7 MAR 03 MEDLINE file segment of TOXCENTER reloaded
NEWS 8 MAR 22 KOREAPAT now updated monthly; patent information enhanced
NEWS 9 MAR 22 Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS 10 MAR 22 PATDPASPC - New patent database available
NEWS 11 MAR 22 REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS 12 APR 04 EPFULL enhanced with additional patent information and new
                fields
     13 APR 04 EMBASE - Database reloaded and enhanced
NEWS
NEWS
     14 APR 18 New CAS Information Use Policies available online
NEWS
    15 APR 25
                Patent searching, including current-awareness alerts (SDIs),
                based on application date in CA/CAplus and USPATFULL/USPAT2
                may be affected by a change in filing date for U.S.
                applications.
NEWS
     16 APR 28
                Improved searching of U.S. Patent Classifications for
                U.S. patent records in CA/CAplus
     17 MAY 23
NEWS
                GBFULL enhanced with patent drawing images
NEWS
     18 MAY 23
                REGISTRY has been enhanced with source information from
                CHEMCATS
NEWS
     19 JUN 06
                The Analysis Edition of STN Express with Discover!
                 (Version 8.0 for Windows) now available
NEWS 20 JUN 13
                RUSSIAPAT: New full-text patent database on STN
                FRFULL enhanced with patent drawing images
NEWS
     21 JUN 13
NEWS 22 JUN 27 MARPAT displays enhanced with expanded G-group definitions
                and text labels
NEWS 23 JUL 01 MEDICONF removed from STN
NEWS 24 JUL 07
                STN Patent Forums to be held in July 2005
NEWS 25 JUL 13
                SCISEARCH reloaded
NEWS 26 JUL 20 Powerful new interactive analysis and visualization software,
                STN AnaVist, now available
NEWS EXPRESS
             JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT
             MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
             AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005
NEWS HOURS
             STN Operating Hours Plus Help Desk Availability
NEWS INTER
             General Internet Information
NEWS LOGIN
             Welcome Banner and News Items
NEWS PHONE
             Direct Dial and Telecommunication Network Access to STN ^{\sigma}
NEWS WWW
             CAS World Wide Web Site (general information)
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 17:59:30 ON 23 JUL 2005

=> file reg
COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION

FILE 'REGISTRY' ENTERED AT 17:59:42 ON 23 JUL 2005 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 JUL 2005 HIGHEST RN 856698-04-9 DICTIONARY FILE UPDATES: 22 JUL 2005 HIGHEST RN 856698-04-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

* The CA roles and document type information have been removed from *

* the IDE default display format and the ED field has been added, *


* effective March 20, 2005. A new display format, IDERL, is now *

* available and contains the CA role and document type information. *

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at: http://www.cas.org/ONLINE/DBSS/registryss.html .

=> Uploading C:\Program Files\Stnexp\Queries\10773002B2.str



chain nodes : 10 11 12 13 ring nodes : 1 2 3 4 5 6 chain bonds : 4-11 5-10 8-12 12-13 ring bonds : 1-2 1-6 2-3 2-7 3-4 3-9 5-6 7-8 8-9 exact/norm bonds : 1-2 1-6 2-3 2-7 3-4 3-9 4 - 54-11 5-6 7-8 exact bonds :

5-10 8-12

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS 11:CLASS 12:CLASS 13:CLASS

STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

STR

Structure attributes must be viewed using STN Express query preparation.

=> s 11 sss sam

SAMPLE SEARCH INITIATED 18:00:04 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED - 14 TO ITERATE

100.0% PROCESSED 14 ITERATIONS 0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 56 TO 504

PROJECTED ANSWERS:

0 TO

0 SEA SSS SAM L1

=> s ll sss ful

FULL SEARCH INITIATED 18:00:14 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED -487 TO ITERATE

100.0% PROCESSED 487 ITERATIONS

23 ANSWERS

SEARCH TIME: 00.00.01

L3 23 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS SINCE FILE TOTAL

> ENTRY SESSION

FULL ESTIMATED COST 161.33 161.54

FILE 'CAPLUS' ENTERED AT 18:00:20 ON 23 JUL 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Jul 2005 VOL 143 ISS 5 FILE LAST UPDATED: 22 Jul 2005 (20050722/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate

```
substance identification.
=> s 13
L4
           15 L3
=> d 14 1-15 bib hitstr
T.4
     ANSWER 1 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
     2005:567104 CAPLUS
ΑN
ΤI
     A preparation of (indazolylamino)pyrrolo[2,1-f][1,2,4]triazine
     derivatives, useful as antiproliferative agents
     Swaminathan, Shankar; Gavai, Ashvinikumar V.; Fan, Junying; Patel, Bharat
IN
     P.; Norris, Derek J.; Corbett, Richard Michael; Zheng, Bin
     Bristol-Myers Squibb Company, USA
PA
SO
     PCT Int. Appl., 51 pp.
     CODEN: PIXXD2
DT
     Patent
LA
     English
FAN.CNT 1
     PATENT NO.
                        KIND
                                           APPLICATION NO.
     WO 2005058245
                        A2
                                20050630 WO 2004-US41920
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
```

```
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
                RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
                        MR, NE, SN, TD, TG
PRAI US 2003-529347P
                                                              20031212 · ·
                                                 P
         US 2004-8719
                                                  Α
                                                              20041209
```

IT 427878-70-4

> RL: RCT (Reactant); RACT (Reactant or reagent) (preparation of (indazolylamino)pyrrolo[2,1-f][1,2,4]triazine derivs. useful as antiproliferative agents)

RN 427878-70-4 CAPLUS CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 1,4-dihydro-5-methyl-4oxo-, ethyl ester (9CI) (CA INDEX NAME)

```
L4
    ANSWER 2 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
```

AN 2005:160831 CAPLUS

142:261564 DN

ΤI Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors, particularly p38 kinases, and their preparation, pharmaceutical compositions, and use

IN Leftheris, Katerina; Wrobleski, Stephen T.; Dyckman, Alaric J.

PA

SO U.S. Pat. Appl. Publ., 29 pp., Cont.-in-part of U.S. Ser. No. 420,399. CODEN: USXXCO

DTPatent

LAEnglish

FAN.CNT 2

PAN.	~IVT	2								•								
	PAT	CENT 1	NO.			KIN	D :	DATE			APPL:					D	ATE	
							-	 -										
PI	US	2005	0433	06	•	A1		2005	0224	1	US 2	003-		20031003				
	US	2004	0825	82		A 1		2004	0429	1	US 20	003-		20030422				
	WO	2005	03783	38		A1		2005	0428	1	WO 2	004-1	JS30	829		2	00409	921
		w:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,
			CN,	co,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,
									IL,									
									MA,									
									PT,									
									UA,									
		RW:	BW,	GH,	GM,	KE,	LS,	MW,	MZ,	NA,	SD,	SL,	SZ,	TZ,	ŪĠ,	ZM,	ZW,	AM,
									ТJ,									
*									HU,									
									CG,									
				TD,			•	•				•	•		•	•	•	
PRAI	US	2002	-374	938P		P		2002	0423									
	US	2003	-420	399		A2		2003	0422									
	US	2003	-678	388		Α		2003	1003									
os	MAI	RPAT	142:	2615	64													

IT 621685-55-0P 621685-56-1P 621685-58-3P

> RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of heteroaryl pyrrolotriazine compds. as p38 kinase inhibitors)

RN 621685-55-0 CAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxaldehyde, 1,4-dihydro-5-methyl-4-oxo-(9CI) (CA INDEX NAME)

RN 621685-56-1 CAPLUS CN Pyrrolo[2,1-f][1,2,4]triazin-4(1H)-one, 6-benzoyl-5-methyl- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} H & O \\ \parallel & C - Ph \\ N & Me \\ O & Me \end{array}$$

RN 621685-58-3 CAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazin-4(1H)-one, 5-methyl-6-[(6-methyl-2-pyridinyl)carbonyl]- (9CI) (CA INDEX NAME)

IT 427878-70-4

RN

CN

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heteroaryl pyrrolotriazine compds. as p38 kinase inhibitors)
427878-70-4 CAPLUS
Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 1,4-dihydro-5-methyl-4-

H C OET

oxo-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2005:130304 CAPLUS

DN 142:392380

TI Synthesis and SAR of 4-(3-hydroxyphenylamino)pyrrolo[2,1-f][1,2,4]triazine based VEGFR-2 kinase inhibitors

AU Borzilleri, Robert M.; Cai, Zhen-Wei; Ellis, Christopher; Fargnoli, Joseph; Fura, Aberra; Gerhardt, Tracy; Goyal, Bindu; Hunt, John T.; Mortillo, Steven; Qian, Ligang; Tokarski, John; Vyas, Viral; Wautlet, Barri; Zheng, Xioping; Bhide, Rajeev S.

CS Departments of Oncology Chemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, 08543-4000, USA

SO Bioorganic & Medicinal Chemistry Letters (2005), 15(5), 1429-1433 CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier B.V.

DT Journal

LA English

IT 310431-29-9P 651744-51-3P 850085-64-2P

850085-66-4P 850085-97-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis and SAR of 4-(3-hydroxyphenylamino)pyrrolo[2,1-f][1,2,4]triazine based VEGFR-2 kinase inhibitors)

RN 310431-29-9 CAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 1,4-dihydro-5-methyl-4-oxo-, methyl ester (9CI) (CA INDEX NAME)

RN 651744-51-3 CAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 1,4-dihydro-5-(1-methylethyl)-4-oxo-, methyl ester (9CI) (CA INDEX NAME)

RN 850085-64-2 CAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 1,4-dihydro-4-oxo-5-propyl-, methyl ester (9CI) (CA INDEX NAME)

RN 850085-66-4 CAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 5-ethoxy-1,4-dihydro-4-oxo-, methyl ester (9CI) (CA INDEX NAME)

RN 850085-97-1 CAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 5-(1,1-dimethylethyl)-1,4-dihydro-4-oxo-, methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} H & O \\ \parallel & C - OMe \\ N & Bu-t \end{array}$$

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:654775 CAPLUS

DN 141:190807

TI Process for preparing pyrrolotriazine kinase inhibitors

IN Chen, Bang-Chi; Zhao, Rulin; Sundeen, Joseph Edward; Leftheris, Katerina; Hynes, John; Wrobleski, Stephen T.

PA USA

SO U.S. Pat. Appl. Publ., 20 pp. CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE

```
PΙ
    US 2004157846
                          A1
                                20040812
                                           US 2004-773002
                                                                   20040205
    WO 2004072030
                          A2
                                           WO 2004-US3223
                                20040826
                                                                   20040205
                          А3
    WO 2004072030
                                20041028
            AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG,
        W:
            BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR,
            CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES,
            ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN,
            IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, KZ, LC,
            LK, LR, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX,
            MZ, MZ, NA, NI
        RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
            BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,
            MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
            GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN,
            GQ, GW, ML, MR, NE, SN, TD, TG
PRAI US 2003-445224P
                         Ρ
                               20030205
  CASREACT 141:190807; MARPAT 141:190807
IT
     310435-15-5P 427878-70-4P
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (process for preparing pyrrolotriazine p38 kinase inhibitors)
RN
     310435-15-5 CAPLUS
CN
     Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 1,4-dihydro-5-methyl-4-
    oxo- (9CI) (CA INDEX NAME)
```

RN 427878-70-4 CAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 1,4-dihydro-5-methyl-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)

```
L4 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:531311 CAPLUS
DN 141:89122
TI Preparation of C-6 modified indazolyl pyrrolotriazines as antiproliferative agents
IN Vite, Gregory D.; Gavai, Ashvinikumar V.; Fink, Brian E.; Mastalerz, Harold; Kadow, John F.
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 81 pp.
```

CODEN: PIXXD2

DTPatent LA English FAN. CNT 1

		_																	
	PA	TENT :	NO.			KIN	D	DATE			APPL	ICAT:	ION	NO.		D	ATE		
PI	WO	0 2004054514					_	20040701		1	WO 2	003-1	US39	20031212					
	WO	2004	0545	14		A3		20041007											
		W:	ΑE,	AG,	AL,	AM,	AT,	ΑU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,	
			CN,	co,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,	
			GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KZ,	LC,	
			LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NI,	NO,	
			NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,	ТJ,	
			TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW		
		RW:	BW,	GH,	GM,	KE,	LS,	MW,	·MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	
			BY,	KG,	ΚZ,	MD,	RU,	ТJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	
			ES,	FI,	FR,	GB,	GR,	HU,	ΙĖ,	IT,	LU,	MC,	NL,	PT,	RO,	SE,	SI,	SK,	
			TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	7
	US	2004	1429	31		A1		2004	0722	•	US 2	003-	7364	76	20031215				
	US	6916	815			B2		2005	0712										
PRAI	US	2002	-433	190P		P		2002	1213										
os	MAI	RPAT	141:	8912	2														
TΨ	42	7878-	70-4	714	971-	30-0													

ΙT 427878-70-4 714971-30-9

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of C-6 modified indazolyl pyrrolotriazines as antiproliferative agents)

RN 427878-70-4 CAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 1,4-dihydro-5-methyl-4oxo-, ethyl ester (9CI) (CA INDEX NAME)

714971-30-9 CAPLUS

Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 5-ethyl-1,4-dihydro-4-oxo-CN , methyl ester (9CI) (CA INDEX NAME)

L4ANSWER 6 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN 2004:120859 CAPLUS ΑN

```
140:181471
DN
     Preparation of pyrrolotriazines as tyrosine kinase activity inhibitors of
TI
     growth factor receptors for the treatment of cancer
     Bhide, Rajeev S.; Borzilleri, Robert M.
IN
     Bristol-Myers Squibb Company, USA
PA
     PCT Int. Appl., 71 pp.
SO
     CODEN: PIXXD2
DT
     Patent
     English
LA
FAN.CNT 1
     PATENT NO.
                            KIND
                                    DATE
                                                 APPLICATION NO.
                                                                            DATE
                            ____
     WO 2004013145
                             A1
PΙ
                                    20040212
                                                 WO 2003-US24273
                                                                            20030804
          W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
              GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
              LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
              PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
         TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
              BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 2004063708
                                               US 2003-633997
                                                                            20030804
                             A1
                                    20040401
                                    20050622 EP 2003-767116,
     EP 1543009
                             A1
                                                                            20030804
              AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
              IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
PRAI US 2002-400572P
                             Ρ
                                    20020802
     WO 2003-US24273
                             W
                                    20030804
OS
     MARPAT 140:181471
IT
     651744-40-0P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
      (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
      (Uses)
         (drug candidate; preparation of pyrrolotriazines as tyrosine kinase activity
         inhibitors of growth factor receptors)
RN
     651744-40-0 CAPLUS
CN
     Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 1,4-dihydro-5-(1-
     methylethyl)-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)
                   OEt
```

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 1,4-dihydro-5-(1-methylethyl)-4-oxo-, hydrazide (9CI) (CA INDEX NAME)

RN 658085-61-1 CAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 1,4-dihydro-5-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)

RN 658085-62-2 CAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 1,4-dihydro-N-methoxy-N-methyl-5-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)

RN 658085-63-3 CAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazin-4(1H)-one, 6-acetyl-5-(1-methylethyl)- (9CI) (CA INDEX NAME)

RN 658085-64-4 CAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 1,4-dihydro-5-(1-methylethyl)-

4-oxo- (9CI) (CA INDEX NAME)

RN 658085-69-9 CAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 1,4-dihydro-5-(1-methylethyl)-4-oxo-, [1-ethoxy-2-(methylsulfonyl)ethylidene]hydrazide (9CI) (CA INDEX NAME)

RN 658085-71-3 CAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide, 1,4-dihydro-5-(1-methylethyl)-4-oxo-N-(2-oxopropyl)- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} H & O & O \\ \parallel & \parallel \\ C-NH-CH_2-C-Me \\ \end{array}$$

L4 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:80847 CAPLUS

DN 140:124558

TI Pyrrolotriazine inhibitors of kinases for use in treatment of diseases associated with growth factor receptor signal transduction

IN Bhide, Rajeev; Cai, Zhen-wei; Qian, Ligang; Barbosa, Stephanie

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 84 pp. CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

PATENT NO.

KIND DATE

APPLICATION NO.

DATE

```
WO 2004009784
                          A2
                                 20040129
PΙ
                                             WO 2003-US22826
                              20040422
                                                                      20030718
     WO 2004009784
                         A3
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2492804
                                 20040129
                                           CA 2003-2492804
                          AΑ
                                                                    20030718
     US 2004063707
                           Α1
                                 20040401
                                             US 2003-622593
                                                                      20030718
     US 2004072832
                                             US 2003-623171
                           A1
                                 20040415
                                                                      20030718
     US 6869952
                                 20050322
                           В2
     EP 1534290
                          A2
                                 20050601
                                            EP 2003-765881
             AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     US 2005124621
                          A1
                                 20050609
                                             US 2005-35248
PRAI US 2002-397256P
                           P
                                 20020719
     US 2003-447213P
                          Ρ
                                 20030213
     US 2003-623171
                                 20030718
                          A1
     WO 2003-US22826
                          W
                                 20030718
     MARPAT 140:124558
os
IT
     427878-70-4
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (pyrrolotriazine inhibitors of kinases for use in treatment of diseases
        associated with growth factor receptor signal transduction)
RN
     427878-70-4 CAPLUS
CN
     Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 1,4-dihydro-5-methyl-4-
     oxo-, ethyl ester (9CI) (CA INDEX NAME)
```

```
L4
     ANSWER 8 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
AN
     2004:80698 CAPLUS
     140:146173
DN
ΤI
     Preparation of pyrrolotriazines as selective VEGFR-2 and FGFR-1 kinase
     inhibitors for treatment of proliferative diseases
IN
     Bhide, Rajeev; Ruel, Rejean; Thibeault, Carl; L'heureux, Alexandre
PA
     Bristol-Myers Squibb Company, USA
     PCT Int. Appl., 66 pp.
SO
     CODEN: PIXXD2
DT
     Patent
LA
     English
FAN.CNT 3
     PATENT NO.
                         KIND
                                DATE
                                           APPLICATION NO.
                                                                    DATE
```

```
WO 2004009601
                                  20040129
                                              WO 2003-US22554
PΙ
                           A1
                                                                       20030718
             AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
              LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
              PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
              KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
              FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
              BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2492665
                                  20040129
                                              CA 2003-2492665
                           AA
                                                                       20030718
     US 2004063707
                                  20040401
                                              US 2003-622593
                           A1
                                                                       20030718
     US 2004072832
                                              US 2003-623171
                                  20040415
                           A1
                                                                       20030718
     US 6869952
                           В2
                                  20050322
     EP 1539763
                           A1
                                  20050615
                                              EP 2003-765754
                                                                       20030718
             AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     US 2005124621
                                  20050609
                                              US 2005-35248
                           Α1
                                                                       20050113
PRAI US 2002-397256P
                           Ρ
                                  20020719
     US 2003-447213P
                           P
                                  20030213
     US 2003-623171
                           A1
                                  20030718
     WO 2003-US22554
                           W
                                  20030718
OS
     MARPAT 140:146173
IT
     651744-51-3
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (preparation of pyrrolotriazines as selective VEGFR-2 and FGFR-1 kinase
        inhibitors for treatment of proliferative diseases)
RN
     651744-51-3 CAPLUS
CN
     Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 1,4-dihydro-5-(1-
     methylethyl)-4-oxo-, methyl ester (9CI) (CA INDEX NAME)
```

IT 651744-40-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrrolotriazines as selective VEGFR-2 and FGFR-1 kinase inhibitors for treatment of proliferative diseases)

RN 651744-40-0 CAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 1,4-dihydro-5-(1methylethyl)-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD

```
ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 9 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
L4
     2004:80644 CAPLUS
AN
DN
     140:146018
ΤI
     Process for preparation of indolyloxypyrrolotriazines and their use as
IN
     Bhide, Rajeev; Fan, Junying; Parlanti, Luca; Barbosa, Stephanie; Qian,
     Ligang; Cai, Zhen-wei; Gibson, Francis S.
PA
     Bristol-Myers Squibb Company, USA
SO
     PCT Int. Appl., 48 pp.
     CODEN: PIXXD2
DT
     Patent
LA
     English.
FAN.CNT 3
                         KIND
     PATENT NO.
                                DATE
                                             APPLICATION NO.
                                                                    DATE
PΙ
     WO 2004009542
                          A2
                                20040129
                                             WO 2003-US22755
                                                                    20030721
     WO 2004009542
                                20040513
                          A3
            AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 2004077858
                          A1
                                 20040422
                                            US 2003-622280
                                                                    20030718
                                             CA 2003-2492861
     CA 2492861
                          AA
                                 20040129
                                                                    20030721
     EP 1554281
                                20050720
                                             EP 2003-765846
                          A2
                                                                    20030721
             AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
                                            US 2005-35248
     US 2005124621
                          Α1
                                 20050609
                                                                    20050113
PRAI US 2002-397256P
                          Ρ
                                 20020719
     US 2003-447213P
                          P
                                 20030213
```

US 2003-623171 A1 WO 2003-US22755 MARPAT 140:146018 OS

US 2003-622280

IT 427878-70-4

RL: RCT (Reactant); RACT (Reactant or reagent)

Α

20030718

20030718

20030721

(process for preparation of indolyloxypyrrolotriazines and their use as drugs)

RN 427878-70-4 CAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 1,4-dihydro-5-methyl-4oxo-, ethyl ester (9CI) (CA INDEX NAME)

```
L4
     ANSWER 10 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
     2003:875265
AN
                 CAPLUS
     139:364963
DN
TI
     Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors,
     particularly p38 kinases, and their preparation, pharmaceutical
     compositions, and use
IN
     Dyckman, Alaric; Leftheris, Katerina; Hynes, John
PA
     Bristol-Myers Squibb Company, USA
     PCT Int. Appl., 45 pp..
SO
     CODEN: PIXXD2
DT
     Patent
LA
     English
FAN.CNT 1
     PATENT NO.
                          KIND
                                 DATE
                                             APPLICATION NO.
                                                                     DATE
     WO 2003091229
                          A1
                                 20031106
PΪ
                                             WO 2003-US12420
                                                                    20030418
         W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
             TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     EP 1503996
                           A1
                                 20050209
                                            EP 2003-718493
                                                                    20030418
             AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     US 2003232831
                          A1
                                 20031218
                                             US 2003-420445
                                                                     20030422
PRAI US 2002-374907P
                           Ρ
                                 20020423
     WO 2003-US12420
                           W
                                 20030418
     MARPAT 139:364963
OS
     621685-55-0P 621685-56-1P 621685-58-3P
IT
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (intermediate; preparation of aryl ketone pyrrolotriazine compds. as p38
        kinase inhibitors)
RN
     621685-55-0 CAPLUS
CN
     Pyrrolo[2,1-f][1,2,4]triazine-6-carboxaldehyde, 1,4-dihydro-5-methyl-4-oxo-
      (9CI)
            (CA INDEX NAME)
```

RN 621685-56-1 CAPLUS CN Pyrrolo[2,1-f][1,2,4]triazin-4(1H)-one, 6-benzoyl-5-methyl- (9CI) (CA INDEX NAME)

$$\bigcap_{N} \bigcap_{N} \bigcap_{C-Ph} \bigcap_{Me}$$

RN 621685-58-3 CAPLUS
CN Pyrrolo[2,1-f][1,2,4]triazin-4(1H)-one, 5-methyl-6-[(6-methyl-2-pyridinyl)carbonyl]- (9CI) (CA INDEX NAME)

IT 427878-70-4

RL: RCT (Reactant); RACT (Reactant or reagent)
 (starting material; preparation of aryl ketone pyrrolotriazine compds. as
 p38 kinase inhibitors)

RN 427878-70-4 CAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 1,4-dihydro-5-methyl-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:875173 CAPLUS

DN 139:381511

TI Pyrrolotriazine aniline compounds useful as kinase inhibitors, particularly p38 kinases, and their preparation, pharmaceutical compositions, and use as antiinflammatory agents

IN Dyckman, Alaric; Hynes, John; Leftheris, Katherina; Liu, Chunjian; Wrobleski, Stephen T.

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 158 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.					KIN	D	DATE		1	APPL	ICAT:	ION 1	NO.		D	DATE				
Ρİ	WO 2003090912 WO 2003090912					2003 2004		1	WO 2	003-1	US12	426		20030415							
		W:	AE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,			
									DM,												
						-		-	IS,	-		-	-	-			-	-			
									MG,												
									SD,												
						-	•	•	VN,	•	•	•	-	,	,	,	,	,			
		RW:	-		•	•	•	•	SD,	•	•	•		7.M.	7.W .	AM.	A7.	BY.			
									AT,												
									IT,												
				•					GA,												
	CA	2483	-	-	-	-	-		1106	•		-	•	-	-						
		1497																			
									FR,												
			•		-			-	MK,		•							,			
	BR	2003	-	-	-				•	•	-	•	•	•				415			
PRAT		2002								•	J., J					_					
os	WO 2003-US12426 MARPAT 139:381511					••			0.10												
TITO		1605				E C .		01.00	-	25											

IT 621685-55-0P 621685-56-1P 621685-58-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyrrolotriazine aniline compds. as p38 kinase inhibitors)

RN 621685-55-0 CAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxaldehyde, 1,4-dihydro-5-methyl-4-oxo-(9CI) (CA INDEX NAME)

RN 621685-56-1 CAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazin-4(1H)-one, 6-benzoyl-5-methyl- (9CI) (CA INDEX NAME)

RN 621685-58-3 CAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazin-4(1H)-one, 5-methyl-6-[(6-methyl-2-pyridinyl)carbonyl]- (9CI) (CA INDEX NAME)

IT 427878-70-4

RL: RCT (Reactant); RACT (Reactant or reagent)
 (starting material; preparation of pyrrolotriazine aniline compds. as p38
 kinase inhibitors)

RN 427878-70-4 CAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 1,4-dihydro-5-methyl-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:777390 CAPLUS

DN 139:292275

TI Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors

IN Godfrey, Jollie Duaine; Hynes, John; Dyckman, Alaric J.; Leftheris, Katerina; Shi, Zhongping; Wrobleski, Stephen T.; Doubleday, Wendel William; Grosso, John A.

PA Bristol-Myers Squibb Company, USA

SO U.S. Pat. Appl. Publ., 36 pp., Cont.-in-part of U.S. Ser. No. 36,293.

CODEN: USXXCO DT Patent English LA FAN.CNT 2 KIND DATE PATENT NO. APPLICATION NO. DATE ____ -----_____ -----PΙ US 2003186982 Α1 20031002 US 2002-289010 20021106 US 6867300 В2 20050315 US 2003069244 **A1** US 2001-36293 20030410 20011107 US 6670357 B2 20031230 ZA 2003003786 Α 20040816 ZA 2003-3786 20030515 US 2004229877 20041118 US 2003-696178 **A**1 20031029 WO 2004043912 A2 20040527 WO 2003-US35220 20031103 WO 2004043912 Α3 20040701 AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, W: CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG US 2005107462 A1 20050519 US 2004-19788 PRAI US 2000-249877P Ρ 20001117 US 2001-310561P Р 20010807 US 2001-36293 A2 20011107 US · 2002-289010 Α 20021106 OS MARPAT 139:292275 IT 427878-70-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrrolotriazine derivative as kinase inhibitor)

RN427878-70-4 CAPLUS

CNPyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 1,4-dihydro-5-methyl-4oxo-, ethyl ester (9CI) (CA INDEX NAME)

```
L4
     ANSWER 13 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
     2003:396849 CAPLUS
AN
     138:401758
DN
TI
     Preparation of 5-substituted N-(1H-indazol-5-yl)pyrrolo[2,1-
     f][1,2,4]triazin-4-amines as antiproliferative agents
IN
     Mastalerz, Harold; Zhang, Guifen; Tarrant, James G.; Vite, Gregory D.
PA
     Bristol-Myers Squibb Company, USA
SO
     PCT Int. Appl., 74 pp.
     CODEN: PIXXD2
DT
     Patent
```

```
LA English FAN.CNT 1
```

W0 2003042172 A2 20030522 W0 2002-US36528 20021112 W1 2003042172 A3 20640129 W1: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG CA 2467068 AA 20030522 CA 2002-2467068 20021112 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK BR 2002014112 A 20040914 BR 2002-14112 20021112 NZ 533034 A 20041126 NZ 2002-294281 20021112 US 2003186983 A1 20031002 US 2002-294281 20021112 US 2003186983 A1 20031002 US 2002-294281 20021112 US 2003186983 A1 20031002 US 2002-294281 20021112 SMARPAT 138:401758 T 310435-15-5p, 5-Methyl-4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RAG (Reactant or reagent) (intermediate; preparation of N-(indazolyl)pyrrolotriazinamines as the kinase inhibitors for treatment of proliferative disorders and other diseases associated with signal transduction pathways)		PAT	PENT	NO.			KIN		DATE			APPL	ICAT	ION	NO.		D.	ATE	
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, II, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG CA 2467068 AA 20030522 CA 2002-2467068 20021112 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK BR 2002014112 A 20040914 BR 2002-14112 20021112 NZ 533034 A 20041126 NZ 2002-533034 20021112 US 2003186983 A1 20031002 US 2002-294281 20021112 US 2003186983 A1 20031002 US 2002-294281 20021114 US 6908916 B2 20050621 RAI US 2001-333014P P 20011114 WO 2002-US36528 W 20021112 MARPAT 138:401758 T 310435-15-5P, 5-Methyl-4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RAG (Reactant or reagent) (intermediate; preparation of N-(indazolyl)pyrrolotriazinamines as t kinase inhibitors for treatment of proliferative disorders and other diseases associated with signal transduction pathways) N 310435-15-5 CAPLUS	PI	WO	2003	0421	 72				2003	0522	,	 WO 2	002-	 US36	 528		2	0021	- 112
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, MI, MR, NE, SN, TD, TG CA 2467068 AA 20030522 CA 2002-2467068 20021112 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK BR 2002014112 A 20040914 BR 2002-14112 A 20040914 BR 2002-14112 DR 2005509030 T2 200550407 JP 2003-333034 A 20041126 A 20050621 US 2003186983 A1 20031002 US 2002-294281 20021112 US 2003186983 A1 20031002 US 2002-294281 20021114 WO 2002-US36528 W 20021112 MARPAT 138:401758 T 310435-15-5p, 5-Methyl-4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RAG (Reactant or reagent) (intermediate; preparation of N-(indazolyl)pyrrolotriazinamines as the kinase inhibitors for treatment of proliferative disorders and other diseases associated with signal transduction pathways) N 310435-15-5 CAPLUS																			
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, MI, MR, NE, SN, TD, TG CA 2467068 AA 20030522 CA 2002-2467068 20021112 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK BR 2002014112 A 20040914 BR 2002-14112 A 20040914 BR 2002-14112 DR 2005509030 T2 200550407 JP 2003-333034 A 20041126 A 20050621 US 2003186983 A1 20031002 US 2002-294281 20021112 US 2003186983 A1 20031002 US 2002-294281 20021114 WO 2002-US36528 W 20021112 MARPAT 138:401758 T 310435-15-5p, 5-Methyl-4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RAG (Reactant or reagent) (intermediate; preparation of N-(indazolyl)pyrrolotriazinamines as the kinase inhibitors for treatment of proliferative disorders and other diseases associated with signal transduction pathways) N 310435-15-5 CAPLUS			W:	ΑE,	AG,	AL,	AM,	AT,	ΑU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG CA 2467068 AA 20030522 CA 2002-2467068 EP 1446401 A2 20040818 EP 2002-793930 20021112 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK BR 2002014112 A 20040914 BR 2002-14112 A 20040126 NZ 2002-233034 A 20041126 NZ 2002-533034 A 20041126 NZ 2002-533034 C0021112 US 2003186983 A1 20031002 US 2002-294281 20021114 US 6908916 B2 20050621 RAI US 2001-333014P P 20011114 WO 2002-US36528 W 20021112 S MARPAT 138:401758 T 310435-15-5p, 5-Methyl-4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RAI (Reactant or reagent) (intermediate; preparation of N-(indazolyl)pyrrolotriazinamines as the kinase inhibitors for treatment of proliferative disorders and other diseases associated with signal transduction pathways) N 310435-15-5 CAPLUS																			
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG CA 2467068 AA 20030522 CA 2002-2467068 20021112 EP 1446401 A2 20040818 EP 2002-793930 20021112 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK BR 2002014112 A 20040914 BR 2002-14112 20021112 NZ 533034 A 20041126 NZ 2002-533034 20021112 JP 2005509030 T2 20050407 JP 2003-544009 20021112 US 2003186983 A1 20031002 US 2002-294281 20021114 US 6908916 B2 20050621 RAI US 2001-333014P P 20011114 WO 2002-US36528 W 20021112 S MARPAT 138:401758 T 310435-15-5P, 5-Methyl-4-oxo-3, 4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RAI (Reactant or reagent) (intermediate; preparation of N-(indazolyl)pyrrolotriazinamines as the kinase inhibitors for treatment of proliferative disorders and other diseases associated with signal transduction pathways) N 310435-15-5 CAPLUS																			
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG CA 2467068 AA 20030522 CA 2002-2467068 20021112 EP 1446401 A2 20040818 EP 2002-793930 20021112 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK BR 2002014112 A 20040914 BR 2002-14112 20021112 NZ 533034 A 20041126 NZ 2002-533034 20021112 JP 2005509030 T2 20050407 JP 2003-544009 20021112 US 2003186983 A1 20031002 US 2002-294281 20021114 US 6908916 B2 20050621 RAI US 2001-333014P P 20011114 WO 2002-US36528 W 20021112 S MARPAT 138:401758 T 310435-15-5P, 5-Methyl-4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RAI (Reactant or reagent) (intermediate; preparation of N-(indazolyl)pyrrolotriazinamines as the kinase inhibitors for treatment of proliferative disorders and other diseases associated with signal transduction pathways) N 310435-15-5 CAPLUS												-				-			
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG CA 2467068 AA 20030522 CA 2002-2467068 20021112 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK BR 2002014112 A 20040914 BR 2002-14112 20021112 NZ 533034 A 20041126 NZ 2002-533034 20021112 JP 2005509030 T2 20050407 JP 2003-544009 20021112 US 2003186983 A1 20031002 US 2002-294281 20021114 WO 2002-US36528 W 20021112 SMARPAT 138:401758 T 310435-15-5p, 5-Methyl-4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RAI (Reactant or reagent) (intermediate; preparation of N-(indazolyl)pyrrolotriazinamines as the kinase inhibitors for treatment of proliferative disorders and other diseases associated with signal transduction pathways) N 310435-15-5 CAPLUS				PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TN,	TR,	TT,	TZ,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG CA 2467068 AA 20030522 CA 2002-2467068 20021112 EP 1446401 A2 20040818 EP 2002-793930 20021112 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK BR 2002014112 A 20040914 BR 2002-14112 20021112 NZ 533034 A 20041126 NZ 2002-533034 20021112 JP 2005509030 T2 20050407 JP 2003-544009 20021112 US 2003186983 A1 20031002 US 2002-294281 20021114 US 6908916 B2 20050621 RAI US 2001-333014P P 20011114 W0 2002-US36528 W 20021112 S MARPAT 138:401758 T 310435-15-5P, 5-Methyl-4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RAG (Reactant or reagent) (intermediate; preparation of N-(indazolyl)pyrrolotriazinamines as the kinase inhibitors for treatment of proliferative disorders and other diseases associated with signal transduction pathways) N 310435-15-5 CAPLUS														·	·			٠,	
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG CA 2467068 AA 20030522 CA 2002-2467068 20021112 EP 1446401 A2 20040818 EP 2002-793930 20021112 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK BR 2002014112 A 20040914 BR 2002-14112 20021112 NZ 533034 A 20041126 NZ 2002-533034 20021112 JP 2005509030 T2 20050407 JP 2003-544009 20021112 US 2003186983 A1 20031002 US 2002-294281 20021114 US 6908916 B2 20050621 RAI US 2001-333014P P 20011114 W0 2002-US36528 W 20021112 S MARPAT 138:401758 T 310435-15-5P, 5-Methyl-4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RAG (Reactant or reagent) (intermediate; preparation of N-(indazolyl)pyrrolotriazinamines as the kinase inhibitors for treatment of proliferative disorders and other diseases associated with signal transduction pathways) N 310435-15-5 CAPLUS			RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG CA 2467068 AA 20030522 CA 2002-2467068 EP 1446401 A2 20040818 EP 2002-793930 20021112 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,																			
CA 2467068 EP 1446401 A2 20040818 EP 2002-793930 20021112 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				FI,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	SK,	TR,	BF,	ВJ,	CF,
EP 1446401 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK BR 2002014112 A 20040914 BR 2002-14112 DR 2033034 A 20041126 DR 2002-533034 DR 2005509030 DR 20050407 DR 2003-544009 DR 2002-1112 DR 2003-544009 DR 2002-1112 DR 2003-544009 DR 2002-1114 DR 2001-333014P DR 2001-333014P DR 20011114 DR 2001-333014P DR 20011114 DR 2002-US36528 DR 20021112 DR ARPAT 138:401758 DR 310435-15-5P, 5-Methyl-4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid DR L: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RAGE (Reactant or reagent) (Intermediate; preparation of N-(indazolyl)pyrrolotriazinamines as the kinase inhibitors for treatment of proliferative disorders and other diseases associated with signal transduction pathways) N 310435-15-5 CAPLUS				CG,	CI,	CM,	GΑ,									TG			
EP 1446401 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK BR 2002014112 A 20040914 BR 2002-14112 DR 2033034 A 20041126 DR 2002-533034 DR 2005509030 DR 20050407 DR 2003-544009 DR 2002-1112 DR 2003-544009 DR 2002-1112 DR 2003-544009 DR 2002-1114 DR 2001-333014P DR 2001-333014P DR 20011114 DR 2001-333014P DR 20011114 DR 2002-US36528 DR 20021112 DR ARPAT 138:401758 DR 310435-15-5P, 5-Methyl-4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid DR L: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RAGE (Reactant or reagent) (Intermediate; preparation of N-(indazolyl)pyrrolotriazinamines as the kinase inhibitors for treatment of proliferative disorders and other diseases associated with signal transduction pathways) N 310435-15-5 CAPLUS		CA	2467	068			AA		2003	0522		CA 2	002-	2467	068		2	0021	112
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK BR 2002014112 A 20040914 BR 2002-14112 20021112 NZ 533034 A 20041126 NZ 2002-533034 20021112 JP 2005509030 T2 20050407 JP 2003-544009 20021112 US 2003186983 A1 20031002 US 2002-294281 20021114 US 6908916 B2 20050621 RAI US 2001-333014P P 20011114 WO 2002-US36528 W 20021112 S MARPAT 138:401758 T 310435-15-5P, 5-Methyl-4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RAG (Reactant or reagent) (intermediate; preparation of N-(indazolyl)pyrrolotriazinamines as the kinase inhibitors for treatment of proliferative disorders and other diseases associated with signal transduction pathways) N 310435-15-5 CAPLUS		ΕP	1446						2004	0818		EP 2	002-	7939	30				
BR 2002014112 A 20040914 BR 2002-14112 20021112 NZ 533034 A 20041126 NZ 2002-533034 20021112 JP 2005509030 T2 20050407 JP 2003-544009 20021112 US 2003186983 A1 20031002 US 2002-294281 20021114 US 6908916 B2 20050621 RAI US 2001-333014P P 20011114 W0 2002-US36528 W 20021112 S MARPAT 138:401758 T 310435-15-5P, 5-Methyl-4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RAG (Reactant or reagent)			R:															MC,	PT,
NZ 533034 JP 2005509030 T2 20050407 JP 2003-544009 20021112 US 2003186983 A1 20031002 US 2002-294281 20021114 US 6908916 B2 20050621 RAI US 2001-333014P P 20011114 WO 2002-US36528 W 20021112 S MARPAT 138:401758 I 310435-15-5P, 5-Methyl-4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RAI (Reactant or reagent) (intermediate; preparation of N-(indazolyl)pyrrolotriazinamines as the kinase inhibitors for treatment of proliferative disorders and other diseases associated with signal transduction pathways) N 310435-15-5 CAPLUS																			
JP 2005509030 T2 20050407 JP 2003-544009 20021112 US 2003186983 A1 20031002 US 2002-294281 20021114 US 6908916 B2 20050621 RAI US 2001-333014P P 20011114 WO 2002-US36528 W 20021112 MARPAT 138:401758 310435-15-5P, 5-Methyl-4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RAI (Reactant or reagent) (intermediate; preparation of N-(indazolyl)pyrrolotriazinamines as the kinase inhibitors for treatment of proliferative disorders and other diseases associated with signal transduction pathways) 310435-15-5 CAPLUS				0141	12		Α		2004	0914		BR 2	002-	1411	2 .		2	0021	112
US 2003186983 Al 20031002 US 2002-294281 20021114 US 6908916 B2 20050621 RAI US 2001-333014P P 20011114 WO 2002-US36528 W 20021112 S MARPAT 138:401758 I 310435-15-5P, 5-Methyl-4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RAI (Reactant or reagent) (intermediate; preparation of N-(indazolyl)pyrrolotriazinamines as to kinase inhibitors for treatment of proliferative disorders and other diseases associated with signal transduction pathways) N 310435-15-5 CAPLUS				134			Α		2004	1126		NZ 2	002-	5330	34		2	0021	112
US 6908916 RAI US 2001-333014P P 20011114 WO 2002-US36528 W 20021112 MARPAT 138:401758 T 310435-15-5P, 5-Methyl-4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RAI (Reactant or reagent) (intermediate; preparation of N-(indazolyl)pyrrolotriazinamines as the kinase inhibitors for treatment of proliferative disorders and other diseases associated with signal transduction pathways) N 310435-15-5 CAPLUS		JP	2005	5090	30		Т2		2005	0407		JP 2	003-	5440	09		2	0021	112
RAI US 2001-333014P P 20011114 WO 2002-US36528 W 20021112 MARPAT 138:401758 January 15-5p, 5-Methyl-4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RAI (Reactant or reagent) (intermediate; preparation of N-(indazolyl)pyrrolotriazinamines as the kinase inhibitors for treatment of proliferative disorders and other diseases associated with signal transduction pathways) 310435-15-5 CAPLUS												US 2	002-	2942	81		2	0021	114
WO 2002-US36528 W 20021112 MARPAT 138:401758 310435-15-5P, 5-Methyl-4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RAG (Reactant or reagent) (intermediate; preparation of N-(indazolyl)pyrrolotriazinamines as twinase inhibitors for treatment of proliferative disorders and other diseases associated with signal transduction pathways) 310435-15-5 CAPLUS																			
MARPAT 138:401758 310435-15-5P, 5-Methyl-4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RAG (Reactant or reagent) (intermediate; preparation of N-(indazolyl)pyrrolotriazinamines as to kinase inhibitors for treatment of proliferative disorders and other diseases associated with signal transduction pathways) 310435-15-5 CAPLUS	RAI																		
310435-15-5P, 5-Methyl-4-oxo-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RAG (Reactant or reagent) (intermediate; preparation of N-(indazolyl)pyrrolotriazinamines as tykinase inhibitors for treatment of proliferative disorders and other diseases associated with signal transduction pathways) N 310435-15-5 CAPLUS	_						W		2002	1112									
<pre>f][1,2,4]triazine-6-carboxylic acid RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RAG (Reactant or reagent) (intermediate; preparation of N-(indazolyl)pyrrolotriazinamines as to kinase inhibitors for treatment of proliferative disorders and other diseases associated with signal transduction pathways) N 310435-15-5 CAPLUS</pre>									_			•	_						
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RAG (Reactant or reagent) (intermediate; preparation of N-(indazolyl)pyrrolotriazinamines as the kinase inhibitors for treatment of proliferative disorders and other diseases associated with signal transduction pathways) N 310435-15-5 CAPLUS	ľ.						_		-		_	opyr	rolo	$\lfloor 2, 1 \rfloor$	_				
(Reactant or reagent) (intermediate; preparation of N-(indazolyl)pyrrolotriazinamines as to kinase inhibitors for treatment of proliferative disorders and other diseases associated with signal transduction pathways) N 310435-15-5 CAPLUS																_			
<pre>(intermediate; preparation of N-(indazolyl)pyrrolotriazinamines as ty kinase inhibitors for treatment of proliferative disorders and other diseases associated with signal transduction pathways) N 310435-15-5 CAPLUS</pre>								(Sy	ntne	tic]	prep	arat	lon)	; PR	EP (Prep	arat	lon)	; RAC
kinase inhibitors for treatment of proliferative disorders and other diseases associated with signal transduction pathways) N 310435-15-5 CAPLUS		(Re								£ 1.T	<i> :</i>	1	1 \		1				
diseases associated with signal transduction pathways) N 310435-15-5 CAPLUS																			
N 310435-15-5 CAPLUS																	rs a	na o	tner
	N	317						MTCU	. sig	IIdT	cran	sauc	CTOU	pat	uway	5)			
	N							iazi	ne-6	-carl	hovy	lic	acid	1	4-4:	hudr	a-5-	meth	v1 – 4 –
oxo- (9CI) (CA INDEX NAME)	, •									Cal	DOAY	110	acid	, 1,	-ul	iryur	U-J-	iiie CII	λτ- 4 -

```
L4
     ANSWER 14 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
AN
     2002:391720 CAPLUS
     136:386144
DN
TТ
     Preparation of pyrrolo[2,1-f][1,2,4]triazine carboxylic acid derivatives
     for use in treating p38 kinase-associated conditions
     Leftheris, Katerina; Barrish, Joel; Hynes, John; Wrobleski, Stephen T.
IN
     Bristol-Myers Squibb Company, USA
PA
SO
     PCT Int. Appl., 108 pp.
     CODEN: PIXXD2
DT
     Patent
ĽΑ
     English
FAN.CNT 2
     PATENT NO.
                         KIND
                                 DATE
                                             APPLICATION NO.
                                                                     DATE
PΙ
     WO 2002040486
                          A2
                                 20020523
                                             WO 2001-US49982
                                                                     20011107
                                20030912
     WO 2002040486
                          A3
            AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
             PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
             US, UZ, VN, YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,
             KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
             IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
             GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2429628
                                 20020523
                          AA
                                             CA 2001-2429628
                                                                     20011107
     AU 2002032760
                          A5
                                 20020527
                                             AU 2002-32760
                                                                     20011107
     EE 200300227
                          Α
                                 20031015
                                             EE 2003-227
                                                                     20011107
     EP 1363910
                          A2
                                 20031126
                                             EP 2001-992298
                                                                     20011107
             AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     JP 2004522713
                          Т2
                                             JP 2002-543494
                                 20040729
                                                                     20011107
     BG 107750
                                             BG 2003-107750
                          Α
                                 20040130
                                                                     20030421
     ZA 2003003786
                          Α
                                 20040816
                                             ZA 2003-3786
                                                                     20030515
     NO 2003002229
                          Α
                                 20030716
                                             NO 2003-2229
                                                                     20030516
PRAI US 2000-249877P
                          Ρ
                                 20001117
     US 2001-310561P
                          Ρ
                                 20010807
     WO 2001-US49982
                          W
                                 20011107
OS MARPAT 136:386144
     310431-29-9P 310435-15-5P 310443-54-0P,
     4-Hydroxy-5-methoxypyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid ethyl
     ester 427878-70-4P
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (intermediate; preparation of pyrrolo[2,1-f][1,2,4]triazine carboxylic acid
        derivs. for use in treating p38 kinase-associated conditions)
RN
     310431-29-9 CAPLUS
```

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 1,4-dihydro-5-methyl-4-oxo-, methyl ester (9CI) (CA INDEX NAME)

RN 310435-15-5 CAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 1,4-dihydro-5-methyl-4-oxo-(9CI) (CA INDEX NAME)

RN 310443-54-0 CAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 1,4-dihydro-5-methoxy-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)

RN 427878-70-4 CAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 1,4-dihydro-5-methyl-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)

```
ANSWER 15 OF 15 CAPLUS COPYRIGHT 2005 ACS on STN
L4
     2000:841986 CAPLUS
AN
DN
     134:17506
ΤI
     Preparation of pyrrolotriazines as kinases inhibitors for treating
     inflammation, cancer, and proliferative diseases
     Hunt, John T.; Bhide, Rajeev S.; Borzilleri, Robert M.; Qian, Ligang
IN
     Bristol-Myers Squibb Company, USA
PA
so
     PCT Int. Appl., 130 pp.
     CODEN: PIXXD2
DT
     Patent
LА
     English
FAN.CNT 1
     PATENT NO.
                          KIND
                                  DATE
                                              APPLICATION NO.
                                                                       DATE
                          ----
                                              ______
                                                                       -----
PΙ
     WO 2000071129
                                  20001130
                                              WO 2000-US13420
                           A1
                                                                       20000516
             AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
             CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
             IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
             MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
             DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
             CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     CA 2373990
                           AA
                                  20001130
                                             CA 2000-2373990
                                                                       20000516
     EP 1183033
                           A1
                                  20020306
                                              EP 2000-930761
                                                                       20000516
             AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     BR 2000010482
                                  20020423
                                              BR 2000-10482
                           Α
                                                                       20000516
                           T2
     JP 2003500359
                                  20030107
                                               JP 2000-619433
                                                                       20000516
     NZ 516292
                           Α
                                  20040130
                                              NZ 2000-516292
                                                                       20000516
     AU 770377
                           B2
                                  20040219
                                              AU 2000-48524
                                                                       20000516
     TR 200103352
                           T2
                                  20050321
                                               TR 2001-200103352
                                                                       20000516
     NO 2001005650
                           Α
                                  20011120
                                              NO 2001-5650
                                                                       20011120
     ZA 2001009577
                           Α
                                  20030220
                                               ZA 2001-9577
                                                                       20011120
PRAI US 1999-135265P
                           P
                                  19990521
     US 2000-193727P
                           Ρ
                                  20000331
     WO 2000-US13420
                           W
                                  20000516
os
     MARPAT 134:17506
     310431-16-4P 310431-29-9P 310435-15-5P
     310436-48-7P 310436-60-3P
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
         (preparation of pyrrolotriazines as kinases inhibitors useful in treating
        inflammation, cancer, and proliferative diseases)
RN
     310431-16-4 CAPLUS
     Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 1,4-dihydro-4-oxo-5-
CN
     phenyl-, ethyl ester (9CI) (CA INDEX NAME)
```

RN 310431-29-9 CAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 1,4-dihydro-5-methyl-4-oxo-, methyl ester (9CI) (CA INDEX NAME)

RN 310435-15-5 CAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 1,4-dihydro-5-methyl-4-oxo-(9CI) (CA INDEX NAME)

RN 310436-48-7 CAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 1,4-dihydro-4-oxo-5-propyl-, ethyl ester (9CI) (CA INDEX NAME)

RN 310436-60-3 CAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 5-ethyl-1,4-dihydro-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)

IT 310443-54-0P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolotriazines as kinases inhibitors useful in treating inflammation, cancer, and proliferative diseases)

RN 310443-54-0 CAPLUS

CN Pyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid, 1,4-dihydro-5-methoxy-4-oxo-, ethyl ester (9CI) (CA INDEX NAME)

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE TOTAL ENTRY SESSION 51.30 212.84

STN INTERNATIONAL LOGOFF AT 18:00:44 ON 23 JUL 2005

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	344	(544/183).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF 	2005/07/23 19:16
L2	40	Bang-Chi.inv. and Chen.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/07/23 19:16
L3	28	Rulin.inv. and Zhao.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/07/23 19:17
L4	79	Joseph.inv. and Sundeen.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/07/23 19:17
L5	. 57	katerina.inv. and Leftheris.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/07/23 19:18
L6	. 68	John.inv. and Hynes.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF .	2005/07/23 19:18
L7	0	Stephen.inv. and Wrobieski.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/07/23 19:19
L8	. 25	Stephen.inv. and Wrobleski.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR .	OFF	2005/07/23 19:19
L9	7	1 and (2 or 3 or 4 or 5 or 6 or 8)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/07/23 19:20

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	344	(544/183).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/07/23 19:16
L2	40	Bang-Chi.inv. and Chen.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/07/23 19:16
L3	28	Rulin.inv. and Zhao.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/07/23 19:17
L4	79	Joseph.inv. and Sundeen.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/07/23 19:17
L5	57	katerina.inv. and Leftheris.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR .	OFF	2005/07/23 19:18
L6	68	John.inv. and Hynes.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR .	OFF	2005/07/23 19:18
L7	. 0	Stephen.inv. and Wrobieski.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/07/23 19:19
L8	25	Stephen.inv. and Wrobleski.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/07/23 19:19
L9	7	1 and (2 or 3 or 4 or 5 or 6 or 8)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2005/07/23 19:20